Therein lies one of the most pragmatic reasons to address health inequity—inaction is financially unsustainable. However, ...

Advances in genetic cell modifications are performed routinely in research laboratories, but clinical translation requires ...

Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic ...

Takeda ( TSE:4502/NYSE:TAK ) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize ...

Investigators from the Mass General Brigham healthcare system will present research discoveries and outcomes from clinical trials at the 2024 American Society of Hematology (ASH) Annual Meeting, held ...

including the incidence of vaso-occlusive crises (severe pain caused when blood vessels are blocked and deprive tissues of ...

The 2023 AABB guidelines overall favor a restrictive transfusion strategy, recommending RBC transfusion for hemoglobin <7 ...

New results from the phase 2/3 HIBISCUS trial of investigational etavopivat in patients with sickle cell disease will be presented to determine the dose for the phase 3 part of the trial, as well as ...

The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme ...

Union Health Minister Jagat Prakash Nadda reveals that over 3,66,000 tribal people in Odisha are carriers of sickle cell ...

Ultimately, whether your doctor prescribes iron infusions or oral supplements, it's important to get to the root cause of ...